Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
ALEC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $6.78
Previous CloseN/A
Volume194.31K
Average Volume (3M)1.17M
Market Cap
$123.99M
Enterprise Value$126.49M
Total Cash (Recent Filing)$413.40M
Total Debt (Recent Filing)$42.52M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Jul 31, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding99,992,600
10 Day Avg. Volume1,599,738
30 Day Avg. Volume1,173,543
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.91
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue0.40
Enterprise Value/Gross Profit1.35
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$4.38Price Target Upside253.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Alector News
PremiumCompany Announcements
Alector Reports Increased Loss, Advances Clinical Pipeline
PremiumCompany Announcements
Alector Announces Resignation of Chief Medical Officer
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAlector completed the enrollment ahead of schedule in April, which probably indicates a strong interest in the therapy.
Financial StabilityAlector announced it has extended its cash runway into second half 2027.
Therapeutic PotentialThe near 100% penetrance for developing FTD-GRN following PGRN mutations suggests a direct causal link, positioning PGRN-targeting latozinemab for meaningful commercial upside.
Bears Say
Future CatalystsThere is no meaningful catalyst expected until Q4 2025, at which time Alector may have less than one year of cash on the balance sheet.
Market OutlookThe base-case valuation range for Alector is set at $1 to $2 with an Underweight rating, indicating limited upside potential.
Therapeutic ChallengesThe success of latozinemab in FTD-GRN does not necessarily translate to success for AL101 in Alzheimer's disease due to the complexity and numerous risk factors associated with Alzheimer's.
Ownership Overview
Currently, No data available
---
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $0.87 and its highest was $6.78 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $123.99M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Jul 31, 2025 which is in 64 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on May 08, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.484 by $0.074.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.46.
How many shares outstanding does Alector Inc have?
Alector Inc has 99,992,600 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.484. Following the earnings report the stock price went up 12.5%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.38 (253.23% Upside)
$4.38 (253.23% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 29.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $151.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.42%
12-Months-Change
Fundamentals
Return on Equity
-90.26%
Trailing 12-Months
Asset Growth
-35.75%
Trailing 12-Months
Company Description
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials, increased collaboration revenue for the quarter, and a strong cash position. However, minimal year-over-year revenue growth and sustained high R&D expenses present challenges.Read More>ALEC Stock 12 Month Forecast
Average Price Target
$4.38
▲(253.23%Upside)
Technical Analysis
Coherus Biosciences
―
Enanta Pharmaceuticals
―
XBiotech
―
C4 Therapeutics
―
Instil Bio
―